

Key	
	Positive (Final)
	Positive (Draft)
	Negative (Final)
	Negative (Draft)
	Terminated

Drug name	Disease	Indication	TA number	NOTES	
GROUP 1					
1	Bosutinib	Chronic myeloid leukaemia (CML)	Previously treated chronic, accelerated and blast phase Philadelphia-chromosome-positive CML when imatinib, nilotinib and dasatinib are not appropriate	TA401	Published August 2016
2	Cetuximab	Head and neck cancer	Recurrent or metastatic squamous cell carcinoma of the head and neck that started in the oral cavity	TA473	Published August 2017
3	Crizotinib	Non-small-cell lung cancer	Previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer	TA422	Published December 2016
4	Dasatinib	Chronic myeloid leukaemia (CML)	Chronic or accelerated phase Philadelphia-chromosome-positive CML that is imatinib resistant or when imatinib cannot be tolerated	TA425	Published December 2016
5	Dasatinib	Chronic myeloid leukaemia (CML)	Untreated chronic phase Philadelphia-chromosome-positive CML	TA426	Published December 2016
6	Everolimus	Renal cell carcinoma	Previously treated advanced renal cell carcinoma	TA432	Published February 2017
7	Everolimus	Breast cancer	Advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease who have had a non-steroidal aromatase inhibitor	TA421	Published December 2016
8	Pemetrexed	Non-small-cell lung cancer	Maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer	TA402	Published August 2016
9	Radium-223 dichloride	Prostate cancer	Hormone-relapsed prostate cancer with bone metastases	TA412	Published September 2016
10	Sorafenib	Hepatocellular carcinoma	Advanced hepatocellular carcinoma in people with Child-Pugh grade A liver impairment	TA474	Published September 2017
11	Trastuzumab emtansine	Breast cancer	Human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane	TA458	Published November 2017
GROUP 2					
12	Abiraterone	Prostate cancer	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	TA387	Published April 2016
13	Brentuximab vedotin	Hodgkin lymphoma	Relapsed or refractory CD30-positive Hodgkin lymphoma	TA446	Published June 2017
14	Cabazitaxel	Prostate cancer	Hormone-relapsed metastatic prostate cancer treated with docetaxel	TA391	Published May 2016
15	Cetuximab	Colorectal cancer	Untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in combination with irinotecan	TA439	Published March 2017
16	Cetuximab	Colorectal cancer	Untreated EGFR-expressing, RAS wild-type metastatic colorectal cancer in combination with oxaliplatin		
17	Panitumumab	Colorectal cancer	Untreated RAS wild-type metastatic colorectal cancer in combination with irinotecan		
18	Panitumumab	Colorectal cancer	Untreated RAS wild-type metastatic colorectal cancer in combination with oxaliplatin		
19	Enzalutamide	Prostate cancer	Metastatic hormone-relapsed prostate cancer before chemotherapy is indicated	TA377	Published January 2016
20	Eribulin	Breast cancer	Locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens	TA423	Published December 2016
21	Ibrutinib	Chronic lymphocytic leukaemia	Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with a 17p deletion or TP53 mutation	TA429	Published January 2017
22	Pertuzumab	Breast cancer	HER2-positive metastatic or locally recurrent unresectable breast cancer	TA509	Published March 2018
GROUP 3					
23	Bortezomib	Multiple myeloma	Relapsed multiple myeloma	TA453	Terminated appraisal - published July 2017
24	Brentuximab vedotin	Lymphoma	Relapsed or refractory systemic anaplastic large cell lymphoma	TA478	Published October 2017

25	Cabozantinib	Thyroid cancer	Progressive, unresectable, locally advanced or metastatic medullary thyroid cancer	TA516	Published March 2018
26	Ibrutinib	non-Hodgkin lymphoma	Waldenstrom's macroglobulinaemia	TA491	Published November 2017
27	Ponatinib	Chronic myeloid leukaemia (CML)	Chronic, accelerated or blast phase CML	TA451	Published June 2017
28	Ponatinib	Acute lymphoblastic leukaemia	Philadelphia-chromosome-positive acute lymphoblastic leukaemia		
29	Regorafenib	Gastrointestinal cancer	Previously treated unresectable or metastatic gastrointestinal stromal tumours	TA488	Published November 2017
30	Sorafenib	Differentiated thyroid cancer	Progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) that does not respond to radioactive iodine	ID1059	Positive draft recommendation - publication expected August 2018
31	Sunitinib	Neuroendocrine tumours	Well- or moderately differentiated unresectable or metastatic neuroendocrine tumours of pancreatic origin in adults with progressive disease	TA449	Published June 2017
32	Vandetanib	Medullary thyroid cancer	Unresectable, locally advanced or metastatic medullary thyroid cancer	ID1415	Negative draft recommendation - publication expected TBC
33	Vismodegib	Basal cell carcinoma	Metastatic basal cell carcinoma, or locally advanced disease that is inappropriate for surgery or radiotherapy	TA400	Published November 2017

NOT APPRAISING			
Bendamustine	Lymphoma	First line	N/A
Bendamustine	Lymphoma	Second line	N/A
Bendamustine	Non-Hodgkin lymphoma	First line	N/A
Bendamustine	Non-Hodgkin lymphoma	Second line	N/A
Bevacizumab	Cervical cancer	First line	N/A
Bevacizumab	Glioma	Third line	N/A
Bevacizumab	Ovarian cancer	First line	N/A
Clofarabine	Leukaemia (acute myeloblastic)	Second line	
Clofarabine	Acute lymphoblastic leukemia	Acute lymphoblastic leukaemia in patients with relapsed or refractory disease in whom the intent is to use treatment as a bridge to bone marrow transplantation	ID1033
Lenalidomide	Myelodysplastic syndromes	First line	N/A
Pegylated liposomal doxorubicin	Sarcoma	Any	N/A
Nelarabine	Lymphoblastic non-Hodgkin lymphoma	Refractory T-cell lymphoblastic non-Hodgkin's lymphoma	ID1044
Nelarabine	Acute lymphoblastic leukaemia	T-cell acute lymphoblastic leukaemia as a bridge to bone marrow transplantation	ID1034
Temsirolimus	Renal cell carcinoma	First-line treatment of advanced renal cell carcinoma in people who have at least 3 of 6 prognostic risk factors	TA178